UVLrx™ European Launch: Targeting 14th Annual Aesthetic & Anti-Aging Medicine World Congress
21.1.2016 07:03 | Business Wire
After a successful North American debut last month at the American Academy of Anti-Aging Medicine (A4M) in Las Vegas, UVLrx Therapeutics™ is pleased to announce the official European launch of its intravenous light therapy treatment system, the model UVL1500, at this year’s 14th Aesthetic & Anti-Aging Medicine World Congress (AMWC) from March 31st to April 2nd. Under the scientific supervision of the World Society of Interdisciplinary Anti-Aging Medicine (WOSIAM), the conference will attract over 10,000 physicians and researchers from more than 120 countries who are interested in the role of prevention in global aesthetic and anti-aging management. At the Congress, UVLrx Therapeutics™ will highlight the clinically proven benefits of light wavelengths utilized by its UVLrx™ Treatment System* for reducing inflammation, a key issue facing the entire $300 billion global industry today.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160120006185/en/
The UVLrx Station™ Model UVL1500 offers the first intravenous, concurrent delivery of ultraviolet-A (UVA) and multiple visible light wavelengths for treating a variety of medical indications. Using the company’s patent-pending Dry Light Adapter™ and a standard IV catheter, the device treats blood intravenously, thus eliminating the need for removal of blood from the body. (Photo: Business Wire)
“Inflammation is a common side effect of all aesthetic procedures, whether they be facial laser treatments, injections or surgery,” said Michael Harter, CEO and president of UVLrx. “By immediately reducing inflammation caused by an aesthetic procedure, our technology will minimize pain and accelerate healing, which in turn will lead to better results and a more satisfied post-op patient.”
“Beyond aesthetic procedures, chronic inflammation can occur due to pathogens in the bloodstream and just everyday stress,” commented Rowland Hanson, chairman of UVLrx. “Left untreated, chronic inflammation accelerates the aging process and has been linked to heart disease, cancer and Alzheimer’s disease. This is why UVLrx is an essential adjunct therapy for physicians practicing both aesthetic and anti-aging medicine.”
In addition to its exhibitor booth at the Congress, UVLrx has secured an adjacent private salon for physician and distributor on-site demonstrations of its CE-marked UVLrx Station™ Model UVL1500. Moreover, UVLrx Chief Science Officer, Ryan Maloney, has been asked to speak at a special session at noon on Friday, April 1st, about the efficacy of ultraviolet light and UVLrx technology for both anti-aging and aesthetics purposes. To ensure that Congress attendees are aware of UVLrx Therapeutics’ participation at AMWC, the company has secured inside front cover advertising, as well as a two-page promotional article, in the March/April issue of PRIME Journal, which will be distributed to all Congress attendees as well as the publication’s nearly 100,000 additional print and online subscribers.
“We look forward to sharing our technology with the global aesthetics and anti-aging community at AMWC 2016 and demonstrating, in person, how the UVLrx Treatment System will benefit all physicians practicing in this field,” added UVLrx CSO Ryan Maloney. “We are especially excited that the theme of the Congress this year is prevention, given the clinically proven ability of the wavelengths utilized by the UVLrx Station™ to immediately reduce inflammation caused by such things as pathogens in the bloodstream, stress and a wide range of aesthetic surgical procedures.”
Ultraviolet blood irradiation (UBI) has been used for over a century to treat bacterial and viral infections and was awarded a Nobel Prize for treating lupus in 1903. Routinely used in hospitals around the world, this form of light therapy fell out of prominence in the U.S. with the advent of antibiotics in the 1950s. With the recent expansion of drug-resistant infections, blood irradiation offers significant advantages to pharmaceutical therapies. Furthermore, UVLrx’s intravenous system is superior to existing ultraviolet blood irradiation (UBI) in that it does not require removal of blood from the body.
To learn more, visit UVLrx.com and stop by the UVLrx Therapeutics booth (F18) at the Congress. Also be sure to attend the lecture “The Must of Detoxification” in Room Auric between 12:00 and 13:00 on Friday, April 1st, to hear from UVLrx Chief Scientist Ryan Maloney.
The UVLrx Station™ Model UVL1500 is not available for sale in the U.S.
* References to published specific wavelength studies available upon request.
About UVLrx Therapeutics
Based in Oldsmar, Florida, UVLrx Therapeutics is dedicated to evidence-based medicine in the field of light therapy and offers the first intravenous, concurrent delivery of ultraviolet-A (UVA) and multiple visible light wavelengths for treating a variety of medical indications. In addition to two Nobel Prizes and NASA-backed research, hundreds of international clinical trials have verified the health benefits of UV and other wavelengths of light utilized in the UVLrx™ Treatment System. For more information, please visit http://uvlrx.com.
About EuroMediCom (organizer of AMWC)
Based in Paris, France, EuroMediCom was co-founded by Catherine Decuyper and Christophe Luino. It is the official organizer of the Aesthetic & Anti-Aging Medicine World Congress (AMWC). This Congress has been launched with a strong belief that effective aging prevention and treatment must be comprehensively addressed integrating two aspects: using aesthetics strategy (dermatology and surgery) for the external appearance, and applying anti-aging medicine for internal well-being. EuroMediCom is not only present in Europe but also partner of many other major congresses in the rest of the world. Since the development of anti-aging medicine, EuroMediCom took an important part in the creation of the first world premier European University Master Program in Preventive, Regenerative and Anti-aging Medicine, recognized today as the best program in the field with an official delivered master degree by the Dresden International University. For more information, please visit http://v1.euromedicom.com/amwc-2016/index.html.
About the World Society of Interdisciplinary Anti-Aging Medicine (WOSIAM)
Based in Paris, France, the World Society of Interdisciplinary Aesthetic and Anti-Aging Medicine (WOSIAM) has quickly become the world's fastest growing anti-aging medicine society to federate international physicians and scientific societies. The main goal of this nonprofit organization is to promote anti-aging medicine through research and educational events for physicians and the general public. The society is predominantly formed by and for physicians. It is the belief of the society's board of directors that the best way for anti-aging medicine to advance is by the endorsement of medical doctors competent in administering safe, evidenced-based anti-aging therapeutics. For more information, please visit http://www.wosiam.org.
About the American Academy of Anti-Aging Medicine (A4M)
Based in Boca Raton, Florida, A4M is a leading nonprofit medical society dedicated to the detection, prevention and treatment of age-related diseases. Dedicated to educating physicians, scientists and the public on biomedical sciences, breaking technologies and preventative medicine issues, the A4M is comprised of over 26,000 members from 120 nations worldwide, including healthcare practitioners, scientists, researchers and governmental officials. For more information, see http://www.a4m.com.
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Study Investigates Performance of Masimo PVi® As Part of Goal-Directed Fluid Therapy During Laparoscopic Bariatric Surgery21.8.2017 06:00 | Pressemelding
Masimo (NASDAQ: MASI) announced today the findings of a recently published study in which researchers at Firat University in Turkey evaluated the performance of Masimo PVi®, a noninvasive and continuous measurement of the dynamic changes in perfusion index (Pi) that occur during respiratory cycles, as the basis of a goal-directed fluid therapy (GDFT) protocol during laparoscopic bariatric surgery on mechanically-ventilated patients.1 In the study, Dr. Demirel and colleagues sought to evaluate whether using GDFT guided by PVi on morbidly obese patients undergoing laparoscopic Roux-en-Y gastric bypass (RYGB) surgery might result in less intravenous fluid use without compromising outcomes. They enrolled 60 patients and divided them randomly into control and GDFT groups. The control group’s fluid levels were managed by standard fluid therapy, using mean arterial pressure (MAP) and
Permasteelisa Group to Join Grandland21.8.2017 04:11 | Pressemelding
Worldwide leading contractor in engineering, project management, manufacturing and installation of architectural envelopes and interior systems, Permasteelisa Group, will join forces with Grandland Group – a fast growing, Shenzhen-based specialist in design and construction of architectural decoration. The strategic alliance will create the biggest, most comprehensive curtain wall player in the world, with exceptional potential for further growth for both companies. Permasteelisa will remain fully committed to build avant-garde architectures and top end, high-quality projects which have become its trademark. The news comes today after LIXIL Group Corporation (LIXIL Group) (TOKYO: 5938) – a global leader in the housing and building industry – announced that it has decided to sell 100% of shares of Permasteelisa S.p.A., held by its major subsidiary LIXIL Corporation, to Grandland Holding
LIXIL to Sell Permasteelisa to Grandland21.8.2017 03:42 | Pressemelding
LIXIL Group Corporation (LIXIL Group) (TOKYO:5938), a global leader in the housing and building industry, today announced that it has decided to sell 100% of the shares of Permasteelisa S.p.A (Permasteelisa) held by its major subsidiary LIXIL Corporation to Grandland Holdings Group Limited (Grandland), a leading Chinese architectural design and construction company. The transaction is subject to customary closing conditions and regulatory approvals, including in China, the United States and Russia. Under the terms of the agreement, the base sale price for Permasteelisa is EURO 467 million. As a result of this transaction and the deconsolidation of Permasteelisa from LIXIL Group, LIXIL Group’s revenue for the full fiscal year ending March 2018 is expected to decrease by approximately 170.0 billion yen from the amount announced on May 8, 2017 (by approximately 9.2% of the previously fore
Samsung Bioepis and Takeda Sign Strategic Collaboration Agreement to Co-Develop Multiple Novel Biologic Therapies20.8.2017 23:30 | Pressemelding
Samsung Bioepis Co., Ltd. announced today that it has entered into a strategic collaboration agreement with Takeda Pharmaceutical Company Limited (TSE: 4502) to jointly fund and co-develop multiple novel biologic therapies in unmet disease areas. The two companies will immediately begin working on the program’s first therapeutic candidate, TAK-671, which is intended to treat severe acute pancreatitis. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170820005028/en/ Christopher Hansung Ko, President & CEO of Samsung Bioepis. (Photo: Business Wire) “Takeda’s extensive knowledge and expertise in drug development makes the company an ideal partner for us as we open a new chapter at Samsung Bioepis,” said Christopher Hansung Ko, President and CEO, Samsung Bioepis. “Five years ago, we entered
The Valence Group Issues Fairness Opinion to SK Capital in Connection with Archroma18.8.2017 13:30 | Pressemelding
The Valence Group has provided a fairness opinion to SK Capital Partners, LP in connection with its recapitalization of Archroma, including investments made by various affiliates of SK Capital. Terms of the transaction were not disclosed. About SK Capital SK Capital is a private investment firm focused on the specialty materials, chemicals and pharmaceutical sectors. The firm builds strong and growing businesses that generate substantial long-term value for its investors. SK Capital utilizes its industry, operating and investment experience to identify opportunities to transform businesses into higher performing companies with improved strategic positioning, growth, profitability and risk profiles. The firm currently has approximately $1.9 billion of assets under management and its portfolio companies generate revenues of over $5.0 billion annually and employ approximat
Biker Summer 2017 campaign: What’s happening during Biker Summer 2017? Moto-tyres.co.uk is giving away exciting prizes!18.8.2017 09:22 | Pressemelding
Whether it’s a short weekend break or a long-distance tour – once again this year Moto-tyres.co.uk is asking bikers from 10 countries about their dream destinations and longest journeys as part of its “Biker Summer 2017” campaign. To ensure than nothing gets in the way of your next tour, the two-wheeler tyre store from Delticom, Europe’s leading online tyre dealer, is entering anyone who completes the survey before 30 September 2017 into a prize draw to win some great biking accessories. Simply answer three short questions about your plans for bike tours this year (don’t forget to provide your name and email address), and with a bit of luck, you might win one of these great prizes. Up for grabs are a GARMIN motorbike GPS system, a GoPro camera with helmet bracket and five 200-Pound vouchers for new motorbike tyres from the online store – thanks to the product range at Moto-tyres.co.uk, eve
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom